drugset / Trial / NCT00108758
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
RandomizedParallel-groupDouble-blindTreatment
Summary
This trial is conducted in Africa, Asia, Europe, South America, and the United States of America (USA). The purpose of this study is to evaluate the effectiveness of secondary prophylactic treatment with NovoSeven® in haemophilia A and B patients with inhibitors.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-11
- Completion
- 2005-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | 90 ug/kg | — |
| Subject | eptacog alfa (activated) | Protein / enzyme biologic | 270 ug/kg | — |